Wuxi Biologics Unspadr2 Stock Price To Book
| 1FW1 Stock | EUR 3.50 0.10 2.94% |
WUXI BIOLOGICS UNSPADR2 fundamentals help investors to digest information that contributes to WUXI BIOLOGICS's financial success or failures. It also enables traders to predict the movement of WUXI Stock. The fundamental analysis module provides a way to measure WUXI BIOLOGICS's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to WUXI BIOLOGICS stock.
WUXI |
WUXI BIOLOGICS UNSPADR2 Company Price To Book Analysis
WUXI BIOLOGICS's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
| Competition |
Based on the latest financial disclosure, WUXI BIOLOGICS UNSPADR2 has a Price To Book of 0.0 times. This is 100.0% lower than that of the Healthcare sector and 100.0% lower than that of the Biotechnology industry. The price to book for all Germany stocks is 100.0% higher than that of the company.
WUXI Price To Book Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses WUXI BIOLOGICS's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of WUXI BIOLOGICS could also be used in its relative valuation, which is a method of valuing WUXI BIOLOGICS by comparing valuation metrics of similar companies.WUXI BIOLOGICS is currently under evaluation in price to book category among its peers.
WUXI Fundamentals
| Return On Equity | 0.12 | |||
| Return On Asset | 0.0551 | |||
| Profit Margin | 0.31 % | |||
| Operating Margin | 0.31 % | |||
| Shares Outstanding | 2.11 B | |||
| Shares Owned By Institutions | 0.01 % | |||
| Price To Earning | 238.12 X | |||
| Revenue | 13.09 B | |||
| Gross Profit | 4.83 B | |||
| EBITDA | 4.6 B | |||
| Net Income | 1.69 B | |||
| Cash And Equivalents | 8.48 B | |||
| Cash Per Share | 4.15 X | |||
| Total Debt | 3.33 B | |||
| Debt To Equity | 0.16 % | |||
| Current Ratio | 3.16 X | |||
| Book Value Per Share | 16.51 X | |||
| Cash Flow From Operations | 1.88 B | |||
| Earnings Per Share | 0.25 X | |||
| Number Of Employees | 10.59 K | |||
| Beta | 1.11 | |||
| Market Capitalization | 32.39 B | |||
| Z Score | 5.4 |
About WUXI BIOLOGICS Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze WUXI BIOLOGICS UNSPADR2's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of WUXI BIOLOGICS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of WUXI BIOLOGICS UNSPADR2 based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in WUXI Stock
WUXI BIOLOGICS financial ratios help investors to determine whether WUXI Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in WUXI with respect to the benefits of owning WUXI BIOLOGICS security.